Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
John P. Fruehauf, University of California, Irvine
ClinicalTrials.gov Identifier:
NCT01321437
First received: March 21, 2011
Last updated: December 6, 2016
Last verified: November 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2019
  Estimated Primary Completion Date: December 2018 (Final data collection date for primary outcome measure)